These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 18057913)

  • 1. New preparations comprising recombinant human growth hormone: deliberations on the issue of biosimilars.
    Ranke MB
    Horm Res; 2008; 69(1):22-8. PubMed ID: 18057913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Similar biological medicinal products containing recombinant human growth hormone: European regulation.
    Pavlovic M; Girardin E; Kapetanovic L; Ho K; Trouvin JH
    Horm Res; 2008; 69(1):14-21. PubMed ID: 18059081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biosimilars and regulatory authorities.
    Minghetti P; Rocco P; Del Vecchio L; Locatelli F
    Nephron Clin Pract; 2011; 117(1):c1-7. PubMed ID: 20689318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. European regulatory guidelines for biosimilars.
    Wiecek A; Mikhail A
    Nephrol Dial Transplant; 2006 Oct; 21 Suppl 5():v17-20. PubMed ID: 16959790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biosimilars: controversies as illustrated by rhGH.
    Declerck PJ; Darendeliler F; Góth M; Kolouskova S; Micle I; Noordam C; Peterkova V; Volevodz NN; Zapletalová J; Ranke MB
    Curr Med Res Opin; 2010 May; 26(5):1219-29. PubMed ID: 20302553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biosimilar medicines--new challenges for a new class of medicine.
    Fox A
    J Biopharm Stat; 2010 Jan; 20(1):3-9. PubMed ID: 20077245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biosimilars: how similar or dissimilar are they?
    Roger SD
    Nephrology (Carlton); 2006 Aug; 11(4):341-6. PubMed ID: 16889575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Biosimilars: regulatory status for approval].
    Herrero Ambrosio A
    Farm Hosp; 2010 Mar; 34 Suppl 1():16-8. PubMed ID: 20920853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biosimilars: pharmacovigilance and risk management.
    Zuñiga L; Calvo B
    Pharmacoepidemiol Drug Saf; 2010 Jul; 19(7):661-9. PubMed ID: 20583204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biosimilars approval process.
    Zuñiga L; Calvo B
    Regul Toxicol Pharmacol; 2010 Apr; 56(3):374-7. PubMed ID: 19925842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biosimilar epoetins and other "follow-on" biologics: update on the European experiences.
    Jelkmann W
    Am J Hematol; 2010 Oct; 85(10):771-80. PubMed ID: 20706990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biosimilars: impact of biologic product life cycle and European experience on the regulatory trajectory in the United States.
    Ahmed I; Kaspar B; Sharma U
    Clin Ther; 2012 Feb; 34(2):400-19. PubMed ID: 22244050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Availability of comparative trials for the assessment of new medicines in the European Union at the moment of market authorization.
    van Luijn JC; Gribnau FW; Leufkens HG
    Br J Clin Pharmacol; 2007 Feb; 63(2):159-62. PubMed ID: 17166187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Legal requirements for the quality of herbal substances and herbal preparations for the manufacturing of herbal medicinal products in the European union.
    Vlietinck A; Pieters L; Apers S
    Planta Med; 2009 Jun; 75(7):683-8. PubMed ID: 19204891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The regulatory framework of biosimilars in the European Union.
    Minghetti P; Rocco P; Cilurzo F; Vecchio LD; Locatelli F
    Drug Discov Today; 2012 Jan; 17(1-2):63-70. PubMed ID: 21856438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Basic facts about biosimilars.
    Nowicki M
    Kidney Blood Press Res; 2007; 30(5):267-72. PubMed ID: 17622764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Follow-on biologics: challenges of the "next generation".
    Schellekens H
    Nephrol Dial Transplant; 2005 May; 20 Suppl 4():iv31-36. PubMed ID: 15827057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biosimilars: opportunity or cause for concern?
    Roger SD; Mikhail A
    J Pharm Pharm Sci; 2007; 10(3):405-10. PubMed ID: 17727803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statistical assessment of biosimilar products.
    Chow SC; Liu JP
    J Biopharm Stat; 2010 Jan; 20(1):10-30. PubMed ID: 20077246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The Polish Task Force position statement on safety of biologic treatment with monoclonal antibodies and soluble receptors].
    Jahnz-Rozyk K; Wiesik-Szewczyk E;
    Pol Merkur Lekarski; 2014 Jul; 37(217):5-9. PubMed ID: 25154192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.